BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today announced that it has secured a contract for the supply of one hundred (100) units of the DE-tector™ explosives trace detection (ETD) system for use at selected airports in Germany, including at the international Frankfurt Airport (FRA). This contract award followed the DE-tector system having successfully met the new European Civil Aviation Conference’s (ECAC) Common Evaluation Process of Security Equipment (CEP) for ai
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. today announced the appointment of Mark Iwicki as Executive Chairman and a member of its board of directors.
PARIS — At the meeting of the French Society of Ophthalmology, Dominique Brémond-Gignac, MD, PhD, talks about ocular allergies in children. There are different treatments options available and can be offered to improve the life of children and their parents.
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today reported financial results for the three months ended March 31, 2015, and provided a business update. First Quarter 2015 and Recent Operational and Financial Highlights Grew sales of Avenova™ by 112% to $465,000 in the first quarter of 2015 over the fourth quarter of 201
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced the publication of pre-clinical data related to the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal PLOS ONE. The published article, “Visual Cycle Modulation as an Approach Towa
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today reported financial results for the three-month period ended March 31, 2015. Company Highlights Successfully implanted 19 Argus® II systems in the first quarter of 2015, the highest number for any quarter to date; Net revenue increased 159% to $1.7 millio